ArticleScientific reports2018
CpG-DNA exerts antibacterial effects by protecting immune cells and producing bacteria-reactive antibodies.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 20 citations in OpenAlex.
- CpG oligodeoxynucleotide reduces PrPMolecules and cells · 2026Article
- Nanostructured branched Y-DNA promotes antitumor immunity through dual activation of cGAS/STING and TLR9.Archives of pharmacal research · 2026Article
- Scaffold vaccination for prevention of orthopedic device infection.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Article
- Cytosolic nucleic acid sensing as driver of critical illness: mechanisms and advances in therapy.Signal transduction and targeted therapy · 2025Review
- Engaging natural antibody responses for the treatment of inflammatory bowel disease via phosphorylcholine-presenting nanofibres.Nature biomedical engineering · 2024Article
- Immunomodulatory Role of Interferons in Viral and Bacterial Infections.International journal of molecular sciences · 2023Review
- Cross-Protection against AcuteVaccines · 2023Article
- Cell death proteins in sepsis: key players and modern therapeutic approaches.Frontiers in immunology · 2023Review
- Bacteria in cancer therapy: A new generation of weapons.Cancer medicine · 2022Review
- Epigenetic adjuvants: durable reprogramming of the innate immune system with adjuvants.Current opinion in immunology · 2022Review
- MyD88-dependent signaling drives toll-like receptor-induced trained immunity in macrophages.Frontiers in immunology · 2022Article
- Platelet CXCL4 mediates neutrophil extracellular traps formation in ANCA-associated vasculitis.Scientific reports · 2021Article
- TLR Agonists as Mediators of Trained Immunity: Mechanistic Insight and Immunotherapeutic Potential to Combat Infection.Frontiers in immunology · 2020Review
- The Central Role and Possible Mechanisms of Bacterial DNAs in Sepsis Development.Mediators of inflammation · 2020Review
- CpG-DNA induces bacteria-reactive IgM enhancing phagocytic activity against Staphylococcus aureus infection.BMB reports · 2019Article
- Anti-Bacterial Effect of CpG-DNA Involves Enhancement of the Complement Systems.International journal of molecular sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CpG-DNA activates various immune cells, contributing to the host defense against bacteria. Here, we examined the biological function of CpG-DNA in the production of bacteria-reactive antibodies. The administration of CpG-DNA increased survival in mice following infection with methicillin-resistant S. aureus and protected immune cell populations in the peritoneal cavity, bone marrow, and spleen. CpG-DNA injection likewise increased bacteria-reactive antibodies in the mouse peritoneal fluid and serum, which was dependent on TLR9. B cells isolated from the peritoneal cavity produced bacteria-reactive antibodies in vitro following CpG-DNA administration that enhanced the phagocytic activity of the peritoneal cells. The bacteria-reactive monoclonal antibody enhanced phagocytosis in vitro and protected mice after S. aureus infection. Therefore, we suggest that CpG-DNA enhances the antibacterial activity of the immune system by protecting immune cells and triggering the production of bacteria-reactive antibodies. Consequently, we believe that monoclonal antibodies could aid in the treatment of antibiotic-resistant bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.